Thursday, April 20, 2023
ANGLE announced that it has signed an agreement with BioView to develop a liquid biopsy circulating tumour cell (CTC) HER2 assay for breast cancer.
This new development partnership opportunity with ANGLE, strengths to develop an impactful liquid biopsy HER2 CTC test. CTCs present a unique opportunity to access protein and/or genomic alterations of HER2 throughout the patient's cancer treatment to help ensure eligibility for the right therapy to improve patient outcomes.
ANGLE and BioView will now begin the programme of developing a HER2 assay for the detection of HER2 protein via immunofluorescence (IF) and HER2/neu gene amplification by FISH, utilising Abbott's PathVysion HER2 DNA probe kit, in CTCs from breast cancer patients' blood samples harvested using ANGLE's FDA cleared Parsortix PC1 Clinical System and analysed using BioView's automated imaging and analysis technology.
The changing market dynamic has provided ANGLE and BioView with a major commercial opportunity to develop a quantitative CTC-based HER2 assay, to assess HER2 protein expression and/or gene amplification levels by analysing fluorescence intensities. Unlike current standard of care tests developed for use on FFPE tissue, a CTC HER2 assay could be used for longitudinal monitoring of HER2 status throughout disease progression, thereby ensuring the patient is targeted for the most appropriate treatment at every stage.